RecruitingPhase 2NCT06176989

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Studying Chondrosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Charalampos Floudas, M.D.
National Cancer Institute (NCI)
Intervention
Enasidenib(drug)
Enrollment
40 enrolled
Eligibility
18-120 years · All sexes
Timeline
20242030

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06176989 on ClinicalTrials.gov

Other trials for Chondrosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Chondrosarcoma

← Back to all trials